Navigation Links
Cell Biosciences Announces First UK System Sale
Date:3/10/2009

PALO ALTO, Calif., March 10 /PRNewswire/ -- Cell Biosciences, Inc., a provider of nanoproteomic analysis systems to life science researchers, today announced the sale of its flagship protein analysis system to The University of Manchester's Stem Cell and Leukaemia Proteomics Laboratory, led by Professor Tony Whetton. Professor Whetton is a pioneer in the use of advanced proteomics technologies to understand biological processes in normal and leukaemic stem cells. The Cell Biosciences system will be used to study how phosphoprotein signaling processes in hematopoietic stem cells are affected during leukaemia.

"My laboratory has developed a number of new methods to look at changes in protein status within cells," said Professor Whetton. "We believe that the Cell Biosciences system will provide important new insights into the effect of leukaemogenic proteins on stem cell processes."

The Cell Biosciences platform is an ultrasensitive nanofluidic immunoassay system designed to analyze extremely small biological samples. Traditional protein analysis techniques can require as many as 100,000 cells, which complicates protein analysis in stem cells and other precious samples. Because of the Cell Biosciences system's high detection sensitivity, it can measure cell signaling proteins reproducibly in as few as 25 cells.

"The University of Manchester is an ideal location for our first UK placement," said Tim Harkness, President and Chief Executive Officer at Cell Biosciences. "We are pleased to see our products adopted by such a prestigious institution."

Cancer research in Manchester recently was rated best in the UK by the government-led Research Assessment Exercise (RAE), a comprehensive assessment of the quality of research at UK universities. The University of Manchester represents the second Cell Biosciences system sale in Europe.

About Cell Biosciences

Cell Biosciences is a private life sciences company focused on nanoproteomics. We develop instrumentation systems and assays for the measurement of phosphoprotein signaling and activation in extremely small biological samples. Our company's lead product is a capillary-based nanofluidic immunoassay platform that provides quantitative and reproducible data on key signaling pathways in precious biological samples, such as small tumor biopsies and stem cells. Cell Biosciences is located in Palo Alto, California.

www.cellbiosciences.com

info@cellbiosciences.com


'/>"/>
SOURCE Cell Biosciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Regado Biosciences to Present at the 2009 Wharton Healthcare Business Conference
2. Neurocrine Biosciences Reports Fourth Quarter and Year-End 2008 Results
3. Enlight Biosciences Expands to direct up to $52 Million to Transformational Enabling Technologies
4. New Jersey-Based Biotech Start-Up Nexomics Biosciences Gets Off the Ground
5. URMC, Lighthouse Biosciences Awarded U.S. Patent for Diagnostic Technology
6. URMC, Lighthouse Biosciences awarded US patent for diagnostic technology
7. Abbott Completes Acquisition of Ibis Biosciences, a Subsidiary of Isis
8. CeloNova BioSciences Receives FDA Market Approval for Embozene(TM) Color-Advanced Microspheres Embolization Platform
9. Pressure BioSciences, Inc. Announces Restructuring, Significant Cost Reduction Initiatives, and Sharpened Focus
10. Alexander R. Giaquinto, Ph.D., Joins Regado Biosciences as Senior Vice President of Regulatory Affairs and Quality Assurance
11. Cell Biosciences Introduces First Protein Analysis Kits
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... ... , ... The homeowner improvement and repair market is expected to reach $317 ... for renovations is also on the rise. Per a 2017 report, 13% of all ... failed to use a licensed contractor.(2) The risks associated with improper renovations—especially tiling—can not ...
(Date:3/26/2017)... Columbus, Ohio (PRWEB) , ... March 26, 2017 ... ... 100 doctors worldwide to receive the RealSelf 100 Award, a prestigious award honoring ... elective cosmetic procedures and to find and connect with doctors and clinics. , ...
(Date:3/25/2017)... ... ... at Swissray is pleased to announce the release of the ELITE DXA, a new ... active scan window, which is more than double that of existing bone densitometers. Historically, ... undergo an accurate total body bone density or body composition study. The ELITE ...
(Date:3/24/2017)... ... 24, 2017 , ... Vighter established its NAEMT Authorized Training ... Prehospital Trauma Life Support (PHTLS) course scholarships to four medics assigned to the ... in cooperation with the American College of Surgeons to promote critical thinking in ...
(Date:3/24/2017)... ... March 24, 2017 , ... Infectious ... to hospitals in the United States, it’s a threat that is constantly changing ... facing infection prevention and offers strategies for the healthcare community to help decrease ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... BOSTON , March 27, 2017 /PRNewswire/ ... company and Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a ... of innovative therapies based upon tetracycline chemistry, announced ... for the treatment of moderate to severe acne ... is a once-daily, oral, narrow spectrum tetracycline-derived antibiotic ...
(Date:3/27/2017)... -- Impax Laboratories, Inc. (NASDAQ: IPXL)today announced that its Board ... as Impax,s President and Chief Executive Officer and a ... Mr. Bisaro will succeed J. Kevin Buchi , ... Officer since December of 2016. With ... Bisaro, 56, is an accomplished global business leader who ...
(Date:3/27/2017)... , March 27, 2017  PhaseRx, Inc. ... for life-threatening inherited liver diseases in children, today ... full year ended December 31, 2016 and provided ... "PhaseRx continued to make progress during the ... positive results from our non-human primate safety study, and ...
Breaking Medicine Technology: